FDMT vs. GHRS, SNDX, IMNM, GYRE, VIR, DNA, XERS, REPL, PHAR, and SANA
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), Gyre Therapeutics (GYRE), Vir Biotechnology (VIR), Ginkgo Bioworks (DNA), Xeris Biopharma (XERS), Replimune Group (REPL), Pharming Group (PHAR), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.
4D Molecular Therapeutics vs. Its Competitors
GH Research (NASDAQ:GHRS) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.
GH Research currently has a consensus target price of $32.00, suggesting a potential upside of 100.13%. 4D Molecular Therapeutics has a consensus target price of $29.56, suggesting a potential upside of 610.47%. Given 4D Molecular Therapeutics' higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than GH Research.
In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than GH Research. MarketBeat recorded 5 mentions for 4D Molecular Therapeutics and 4 mentions for GH Research. 4D Molecular Therapeutics' average media sentiment score of 0.49 beat GH Research's score of 0.35 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.
GH Research has higher earnings, but lower revenue than 4D Molecular Therapeutics. GH Research is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
GH Research has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.81, suggesting that its share price is 181% more volatile than the S&P 500.
GH Research has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. GH Research's return on equity of -19.20% beat 4D Molecular Therapeutics' return on equity.
56.9% of GH Research shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
4D Molecular Therapeutics beats GH Research on 8 of the 14 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FDMT) was last updated on 7/16/2025 by MarketBeat.com Staff
